ArticleFrontiers in medicine2026
Clinical characteristics of leukemic optic nerve infiltration in pediatric acute lymphoblastic leukemia: 3 cases and a literature review.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric optic nerve infiltration in acute lymphoblastic leukemia (ALL) is a rare yet critical neuro-ophthalmic emergency, often signaling central nervous system (CNS) involvement or relapse. In this case series we present three cases of optic nerve infiltration in pediatric patients with ALL. The patients underwent systemic chemotherapy, intrathecal chemotherapy, and, in some instances, orbital radiation therapy, leading to varying degrees of visual recovery. In addition to presenting these cases, we review the existing literature and discuss the pathogenesis, clinical features, diagnostic approaches, imaging findings, and treatment strategies for this condition. Based on our cases and prior reports, we outline a practical diagnostic and treatment framework that prioritizes early recognition to reduce the risk of irreversible vision loss. For relapse or refractory disease, intensified therapy may be considered, including chimeric antigen receptor CD19 CAR T-cell therapy and hematopoietic stem cell transplantation. Optic nerve infiltration in ALL requires prompt, coordinated management among hematology, oncology, and ophthalmology specialists. Timely and appropriately intensified treatment may improve visual outcomes and survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.